866546-09-0

Basic information

• Product Name: 3-bromo-5-chloro-1H-pyrrolo[2,3-b]pyridine
• Synonyms: 3-bromo-5-chloro-1H-pyrrolo[2,3-b]pyridine;3-Bromo-5-chloro-7-azaindole
• CAS NO: 866546-09-0
• Molecular Formula: C₇H₄BrClN₂
• Molecular Weight: 231.48
• Product Categories: CHIRAL CHEMICALS
• Mol File: 866546-09-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 240°
• Boiling Point: 350.4 °C at 760 mmHg
• Flash Point: 165.7 °C
• Appearance: /
• Density: 1.878 g/cm³
• Vapor Pressure: 8.93E-05mmHg at 25°C
• Refractive Index: 1.73
• Storage Temp.: 2-8°C
• PKA: 11.30±0.40(Predicted)
• CAS DataBase Reference: 3-bromo-5-chloro-1H-pyrrolo[2,3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-5-chloro-1H-pyrrolo[2,3-b]pyridine(866546-09-0)
• EPA Substance Registry System: 3-bromo-5-chloro-1H-pyrrolo[2,3-b]pyridine(866546-09-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 866546-09-0(Hazardous Substances Data)

Usage

General Description

3-bromo-5-chloro-1H-pyrrolo[2,3-b]pyridine is a synthetic organic compound that belongs to the class of organic compounds known as pyrrolo[2,3-b]pyridines. It is typically used in research or laboratory settings due to its specific structure and properties. It is characterized by a pyrrolo[2,3-b]pyridine core structure, which contains a pyrrolidine ring fused with a pyridine ring. Further, this compound is characterized by bromine and chlorine substituents in its molecular structure. Due to its potential use in pharmaceuticals and drug design studies, it is of particular interest to researchers and chemists. However, information regarding its toxicity, reactivity, and environmental impacts is yet unavailable or limited and hence should be handled with caution.

InChI:InChI=1/C7H4BrClN2/c8-6-3-11-7-5(6)1-4(9)2-10-7/h1-3H,(H,10,11)

Upstream product

• 866318-90-3 2-amino-5-chloro-3-[(trimethylsilyl)ethynyl]pyridine 
• 211308-81-5 5-chloro-3-iodo-2-aminopyridine 
• 1072-98-6 5-chloro-2-pyridylamine 
• 866546-07-8 5-chloro-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 866546-10-3 3-bromo-5-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 866546-11-4 5-chloro-1-(p-tolylsulfonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine 
• 1346172-63-1 (2S,3S)-3-{[tert-butyl(dimethyl)silyl]oxy}-1-(6-(5-chloro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazin-2-yl)-N-(2,2,2-trifluoroethyl)azetidine-2-carboxamide 
• 1346172-68-6 tert-butyl (3R)-4-(6-{5-chloro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrazin-2-yl)-3-[(2,2,2-trifluoroethyl)carbamoyl]piperazine-1-carboxylate 
• 1346172-70-0 (2R)-1-(6-{5-chloro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}pyrazin-2-yl)-N-(2,2,2-trifluoroethyl)piperazine-2-carboxamide hydrochloride 
• 1346172-78-8 2-(3-{5-chloro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridine-3-yl}-5H-pyrrolo[2,3-b]pyrazin-5-yl)-N-(2,2,2-trifluoroethyl)acetamide 
• 1346172-81-3 methyl 1-[(6-{5-chloro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-pyrazin-2-yl)oxy]cyclopropanecarboxylate 
• 1346172-89-1 methyl 6-{5-chloro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-pyrazine-2-carboxylate 
• 1346172-93-7 diethyl (6-{5-chloro-1-[(4-methylphenyl)sulfonyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-pyrazin-2-yl)propanedioate 
• 1363407-75-3 potassium (5-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)trifluoroborate 
• 1346172-28-8 tert-butyl N-{6-[5-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrazin-2-yl}-L-alaninate 
• 1259277-59-2 N-[(1S, 2S)-2-[[2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl]amino]cyclohexyl]acetamide 
• 1259278-56-2 (1S,2S)-N₁-(2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl)cyclohexane-1,2-diamine 
• 1259277-58-1 (1S,2S)-N₁-(2-(5-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-yl)cyclohexane-1,2-diamine 

Relevant articles and documents

6-Methyl-7-Aryl-7-Deazapurine Nucleosides as Anti-Trypanosoma cruzi Agents: Structure-Activity Relationship and in vivo Efficacy

Chagas disease is a tropical infectious disease resulting in progressive organ-damage and currently lacks efficient treatment and vaccine options. The causative pathogen, Trypanosoma cruzi, requires uptake and processing of preformed purines from the host because it cannot synthesize these de novo, instigating the evaluation of modified purine nucleosides as potential trypanocides. By modifying the pyrimidine part of a previously identified 7-aryl-7-deazapurine nucleoside, we found that substitution of a 6-methyl for a 6-amino group allows retaining T. cruzi amastigote growth inhibitory activity but confers improved selectivity towards mammalian cells. By keeping the 6-methyl group unaltered, and introducing different 7-aryl groups, we identified several analogues with sub-micromolar antitrypanosomal activity. The 7-(4-chlorophenyl) analogue 14, which was stable in microsomes, was evaluated in an acute mouse model. Oral administration of 25 mg/kg b.i.d. suppressed peak parasitemia and protected mice from infection-related mortality, gave similar reductions as the reference drug of blood parasite loads determined by qPCR, but as benznidazole failed to induce sterile cure in the short time period of drug exposure (5 days).

PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF INFLUENZA VIRUS REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas l-lll, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating a variety of diseases and disorders.